TAO Synergies (TAOX) Receivables - Other (2020)
TAO Synergies' (TAOX) quarterly Receivables - Other came in at $127445.0 in Q4 2020, down 85.21% quarter-over-quarter from $861852.0 in Q3 2020.
Powered by 
Analysis
TAO Synergies (TAOX) Receivables - Other (2020) Analysis & Trends
TAO Synergies (TAOX) has reported Receivables - Other for 1 consecutive years, with $127445.0 the latest figure, recorded in Q4 2020.
- For the quarter ending Q4 2020, Receivables - Other changed N/A year-over-year to $127445.0; the trailing twelve-month figure through Dec 2020 stood at $127445.0 (changed N/A YoY), and the FY2020 full-year result was $127445.0, changed N/A from the prior year.
- Receivables - Other declined to $127445.0 in Q4 2020 per TAOX's latest filing, from $861852.0 in the prior quarter.
- Across five years, Receivables - Other topped out at $861852.0 in Q3 2020 and bottomed at $127445.0 in Q4 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 211.51 Bn | 197.52 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 181.48 Bn | 178.30 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.45 Bn | 124.60 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.87 Bn | 74.88 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.59 Bn | 56.41 Bn | 1.37 Bn |
| 6 | Moderna | 54.72 Bn | 49.59 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.13 Bn | 30.82 Bn | 992.69 Mn |
| 8 | Biogen | 31.29 Bn | 30.01 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.31 Bn | 30.31 Bn | 1.16 Mn |
| 10 | TAO Synergies | 30.90 Mn | 30.90 Mn | - |